PT  - JOURNAL ARTICLE
AU  - Andy Q. Yuan
AU  - Likun Zhao
AU  - Lili Bai
AU  - Qingwu Meng
AU  - Zhenguo Wen
AU  - Yanhu Li
AU  - Daqing Guo
AU  - Shanshan Zhen
AU  - Xiaojun Chen
AU  - Ji Yang
AU  - Xiaoying Xue
TI  - Isolation of and Characterization of Neutralizing Antibodies to Covid-19 from a Large Human Naïve scFv Phage Display Library
AID  - 10.1101/2020.05.19.104281
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.05.19.104281
4099  - http://biorxiv.org/content/early/2020/05/19/2020.05.19.104281.short
4100  - http://biorxiv.org/content/early/2020/05/19/2020.05.19.104281.full
AB  - SARS-CoV-2 (Covid-19) has caused currently ongoing global plague and imposed great challenges to health managing systems all over the world, with millions of infections and hundreds of thousands of deaths. In addition to racing to develop vaccines, neutralizing antibodies (nAbs) to this virus have been extensively sought and are expected to provide another prevention and therapy tool against this frantic pandemic. To offer fast isolation and shortened early development, a large human naïve phage display antibody library, was built and used to screen specific nAbs to the receptor-binding domain, RBD, the key for Covid-19 virus entry through a human receptor, ACE2. The obtained RBD-specific antibodies were characterized by epitope mapping, FACS and neutralization assay. Some of the antibodies demonstrated spike-neutralizing property and ACE2-competitiveness. Our work proved that RBD-specific neutralizing binders from human naïve antibody phage display library are promising candidates to for further Covid-19 therapeutics development.Competing Interest StatementAndy Yuan is the co-founder and CSO of Yikesite Biopharma Development LLC, which wholly-owns Excyte LLC. Qingwu Meng is the co-founder of Yikesite Biopharma Development LLC. Likun Zhao, Lili Bai, Yanhu Li, Daqing Guo, Shanshan Zhen, Xiaojun Chen，Ji Yang and Xiaoying Xue are the employees of Yikesite Biopharma Development LLC.